These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 36619856)

  • 1. Endocrine and multiple sclerosis outcomes in patients with autoimmune thyroid events in the alemtuzumab CARE-MS studies.
    Dayan CM; Lecumberri B; Muller I; Ganesananthan S; Hunter SF; Selmaj KW; Hartung HP; Havrdova EK; LaGanke CC; Ziemssen T; Van Wijmeersch B; Meuth SG; Margolin DH; Poole EM; Baker DP; Senior PA
    Mult Scler J Exp Transl Clin; 2023; 9(1):20552173221142741. PubMed ID: 36619856
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Quality of Life Improves with Alemtuzumab Over 6 Years in Relapsing-Remitting Multiple Sclerosis Patients with or without Autoimmune Thyroid Adverse Events: Post Hoc Analysis of the CARE-MS Studies.
    Bertolotto A; Arroyo R; Celius EG; Comi G; Havrdova EK; Honeycutt WD; Hunter SF; Izquierdo G; Kornek B; Miller T; Mitsikostas DD; Singer BA; Ziemssen T; Chung L; Daizadeh N; Afsar S; Hashemi L; Senior P
    Neurol Ther; 2020 Dec; 9(2):443-457. PubMed ID: 32410147
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Alemtuzumab-induced autoimmune thyroid events in patients with relapsing-remitting multiple sclerosis: A real-life and monocentric experience at a tertiary-level centre.
    Manso J; Zhu YH; Margoni M; Rinaldi F; Censi S; Carducci S; Cosma C; Plebani M; Gallo P; Mian C
    Clin Endocrinol (Oxf); 2022 Sep; 97(3):331-338. PubMed ID: 34724236
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy of alemtuzumab over 6 years in relapsing-remitting multiple sclerosis patients who relapsed between courses 1 and 2: Post hoc analysis of the CARE-MS studies.
    Van Wijmeersch B; Singer BA; Boster A; Broadley S; Fernández Ó; Freedman MS; Izquierdo G; Lycke J; Pozzilli C; Sharrack B; Steingo B; Wiendl H; Wray S; Ziemssen T; Chung L; Margolin DH; Thangavelu K; Vermersch P
    Mult Scler; 2020 Nov; 26(13):1719-1728. PubMed ID: 31675266
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pregnancy outcomes and postpartum relapse rates in women with RRMS treated with alemtuzumab in the phase 2 and 3 clinical development program over 16 years.
    Oh J; Achiron A; Celius EG; Chambers C; Derwenskus J; Devonshire V; Hellwig K; Hutton GJ; McCombe P; Moore M; Rog D; Schneider JR; Simm RF; Sousa L; Vincent SG; Chung L; Daizadeh N; Mitchell C; Compston DAS;
    Mult Scler Relat Disord; 2020 Aug; 43():102146. PubMed ID: 32498033
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety and efficacy with alemtuzumab over 13 years in relapsing-remitting multiple sclerosis: final results from the open-label TOPAZ study.
    Coles AJ; Achiron A; Traboulsee A; Singer BA; Pozzilli C; Oreja-Guevara C; Giovannoni G; Comi G; Freedman MS; Ziemssen T; Shiota D; Rawlings AM; Wong AT; Chirieac M; Montalban X
    Ther Adv Neurol Disord; 2023; 16():17562864231194823. PubMed ID: 37745914
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and Safety of Alemtuzumab in Patients of African Descent with Relapsing-Remitting Multiple Sclerosis: 8-Year Follow-up of CARE-MS I and II (TOPAZ Study).
    Okai AF; Amezcua L; Berkovich RR; Chinea AR; Edwards KR; Steingo B; Walker A; Jacobs AK; Daizadeh N; Williams MJ;
    Neurol Ther; 2019 Dec; 8(2):367-381. PubMed ID: 31654272
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Best Practices for Long-Term Monitoring and Follow-Up of Alemtuzumab-Treated MS Patients in Real-World Clinical Settings.
    Barclay K; Carruthers R; Traboulsee A; Bass AD; LaGanke C; Bertolotto A; Boster A; Celius EG; de Seze J; Cruz DD; Habek M; Lee JM; Limmroth V; Meuth SG; Oreja-Guevara C; Pagnotta P; Vos C; Ziemssen T; Baker DP; Wijmeersch BV
    Front Neurol; 2019; 10():253. PubMed ID: 30967831
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Alemtuzumab-related thyroid dysfunction in a phase 2 trial of patients with relapsing-remitting multiple sclerosis.
    Daniels GH; Vladic A; Brinar V; Zavalishin I; Valente W; Oyuela P; Palmer J; Margolin DH; Hollenstein J
    J Clin Endocrinol Metab; 2014 Jan; 99(1):80-9. PubMed ID: 24170099
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Alemtuzumab-Induced Autoimmune Thyroid Dysfunction.
    Ragavan S; Elhelw O; Majeed W; Kyriacou A; Syed A
    Cureus; 2022 Mar; 14(3):e22751. PubMed ID: 35371892
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Graves' disease after treatment with alemtuzumab for multiple sclerosis.
    Tsourdi E; Gruber M; Rauner M; Blankenburg J; Ziemssen T; Hofbauer LC
    Hormones (Athens); 2015; 14(1):148-53. PubMed ID: 25402383
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Graves' disease induced by Alemtuzumab in relapsing-remitting multiple sclerosis patients: an observational study in a reference center.
    Rodríguez de Vera Gómez P; García-González JJ; Ravé-García R; López Ruiz R; Torres-Cuadro A; Eichau-Madueño S; García-García C; Martín-Hernández T
    J Endocrinol Invest; 2022 Oct; 45(10):1977-1990. PubMed ID: 35718853
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Development of Autoimmune Thyroid Disease in Multiple Sclerosis Patients Post-Alemtuzumab Improves Treatment Response.
    Sovetkina A; Nadir R; Scalfari A; Tona F; Murphy K; Rigoni E; Dorsey R; Malik O; Nandoskar A; Singh-Curry V; Nicholas R; Martin N
    J Clin Endocrinol Metab; 2020 Sep; 105(9):. PubMed ID: 32667988
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Alemtuzumab-induced thyroid events in multiple sclerosis: a systematic review and meta-analysis.
    Scappaticcio L; Castellana M; Virili C; Bellastella G; Centanni M; Cannavò S; Campennì A; Ruggeri RM; Giovanella L; Trimboli P
    J Endocrinol Invest; 2020 Feb; 43(2):219-229. PubMed ID: 31452116
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Thyroid autoimmunity following alemtuzumab treatment in multiple sclerosis patients: a prospective study.
    Kazakou P; Tzanetakos D; Vakrakou AG; Tzartos JS; Evangelopoulos ΜE; Anagnostouli M; Stathopoulos P; Kassi GN; Stefanis L; Kilidireas C; Zapanti E
    Clin Exp Med; 2023 Oct; 23(6):2885-2894. PubMed ID: 36641771
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immune reconstitution after alemtuzumab therapy for multiple sclerosis triggering Graves' orbitopathy: a case series.
    Roos JCP; Moran C; Chatterjee VK; Jones J; Coles A; Murthy R
    Eye (Lond); 2019 Feb; 33(2):223-229. PubMed ID: 30498266
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Proportion of alemtuzumab-treated patients converting from relapsing-remitting multiple sclerosis to secondary progressive multiple sclerosis over 6 years.
    Horáková D; Boster A; Bertolotto A; Freedman MS; Firmino I; Cavalier SJ; Jacobs AK; Thangavelu K; Daizadeh N; Poole EM; Baker DP; Margolin DH; Ziemssen T;
    Mult Scler J Exp Transl Clin; 2020; 6(4):2055217320972137. PubMed ID: 33414927
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hashimoto's thyroiditis following Graves' disease.
    Umar H; Muallima N; Adam JM; Sanusi H
    Acta Med Indones; 2010 Jan; 42(1):31-5. PubMed ID: 20305330
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact of alemtuzumab on health-related quality of life over 6 years in CARE-MS II trial extension patients with relapsing-remitting multiple sclerosis.
    Arroyo R; Bury DP; Guo JD; Margolin DH; Melanson M; Daizadeh N; Cella D
    Mult Scler; 2020 Jul; 26(8):955-963. PubMed ID: 31144568
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lymphocyte pharmacodynamics are not associated with autoimmunity or efficacy after alemtuzumab.
    Wiendl H; Carraro M; Comi G; Izquierdo G; Kim HJ; Sharrack B; Tornatore C; Daizadeh N; Chung L; Jacobs AK; Hogan RJ; Wychowski LV; Van Wijmeersch B;
    Neurol Neuroimmunol Neuroinflamm; 2020 Jan; 7(1):. PubMed ID: 31662412
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.